Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

vetviva richter gmbh - procainum hýdróklóríð - stungulyf, lausn - 20 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

abbvie a/s - botulinum toxin type a - stungulyfsstofn, lausn - 100 allergan ein.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - tagraxofusp - lymphoma - Æxlishemjandi lyf - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

Evrópusambandið - íslenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - mergæxli - Æxlishemjandi lyf - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

santen oy - ciclosporin - kviðsjúkdómar - augnlækningar - meðferð við alvarlegum glærubólgu hjá fullorðnum sjúklingum með þurr auganu, sem hefur ekki batnað þrátt fyrir meðferð með tárubólgu.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

santen oy - ciclosporin - conjunctivitis; keratitis - augnlækningar - meðferð alvarlega vernal keratoconjunctivitis (vkc) í börn frá 4 ára aldri og unglingar.